Trial Profile

A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (Aripiprazole, Olanzapine, Quetiapine, or Risperidone)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aripiprazole (Primary) ; Olanzapine (Primary) ; Quetiapine (Primary) ; Risperidone (Primary)
Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
Focus Therapeutic Use
Acronyms hummingbird
Sponsors Otsuka Pharmaceutical Development & Commercialization

07 Oct 2020 New trial record
15 Sep 2020 Results presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com